# Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance

> **NCT00046033** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 118 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Lopinavir/ritonavir
- **DRUG:** Ritonavir
- **DRUG:** Saquinavir
- **DRUG:** Tenofovir disoproxil fumarate
- **DRUG:** Amprenavir

## Key facts

- **NCT ID:** NCT00046033
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 2003-03
- **Final completion:** —
- **Target enrollment:** 118 (—)
- **Last updated:** 2011-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00046033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00046033, "Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00046033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*